Updated Jul 16, 2026
Monia Brett P has filed 3 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $43.06M.

Brett P. Monia is the Chief Executive Officer and Director of Ionis Pharmaceuticals, a leader in antisense technology for drug development. Under his leadership, Ionis has focused on innovative treatments for various diseases, including cardiovascular and neurological conditions.
| Role | Chief Executive Officer, Director |
|---|---|
| Notability | 50/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-26 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 50.0K | $80.59 | $4.03M |
| 2026-06-26 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise | 50.0K | $56.78 | $2.84M |
| 2026-06-26 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 21.1K | $78.49 | $1.65M |
| 2026-06-26 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise | 21.1K | $32.60 | $687K |
| 2026-06-26 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 14.6K | $78.41 | $1.14M |
| 2026-06-26 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise | 14.6K | $32.60 | $475K |
| 2026-06-22 | CGTX | COGNITION THERAPEUTICS INC | A — Grant or award | 25.0K | $0.00 | |
| 2026-05-15 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 3.2K | $78.68 | $253K |
| 2026-05-15 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise | 3.2K | $32.60 | $105K |
| 2026-05-15 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 1.3K | $78.01 | $103K |
| 2026-05-15 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise | 1.3K | $32.60 | $43K |
| 2026-03-11 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 17.6K | $76.34 | $1.34M |
| 2026-03-11 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 16.5K | $75.47 | $1.25M |
| 2026-03-11 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise [10b5-1] | 34.1K | $60.89 | $2.08M |
| 2026-03-11 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 1.7K | $75.58 | $127K |
| 2026-03-11 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 117.6K | $75.26 | $8.85M |
| 2026-03-11 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 7.4K | $74.11 | $547K |
| 2026-03-11 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise [10b5-1] | 73.5K | $60.89 | $4.48M |
| 2026-03-11 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise [10b5-1] | 40.8K | $60.89 | $2.49M |
| 2026-03-03 | IONS | IONIS PHARMACEUTICALS INC | J — Other acquisition / disposition | 484 | $48.87 | $24K |
Brett P. Monia is the Chief Executive Officer and Director of Ionis Pharmaceuticals, a leader in antisense technology for drug development. Under his leadership, Ionis has focused on innovative treatments for various diseases, including cardiovascular and neurological conditions.…
3 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 20 open-market sales ($43.06M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Monia Brett P profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.